We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment‐induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin‐releasing hormone antagonists or agonists.
- Authors
Kijima, Toshiki; Ito, Masaya; Ishioka, Junichiro; Matsuoka, Yoh; Saito, Kazutaka; Fujii, Yasuhisa
- Abstract
Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists Abbreviations & Acronyms ADT androgen deprivation therapy BNP brain natriuretic peptide CVD cardiovascular disease GnRH gonadotropin-releasing hormone ADT, which is the mainstay of treatment for advanced prostate cancer, can be achieved with orchiectomy or medical castration. A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).
- Subjects
LUTEINIZING hormone releasing hormone agonists; BRAIN natriuretic factor; PROSTATE cancer patients; HORMONE antagonists; GONADOTROPIN releasing hormone; INSTITUTIONAL review boards
- Publication
International Journal of Urology, 2020, Vol 27, Issue 4, p354
- ISSN
0919-8172
- Publication type
Article
- DOI
10.1111/iju.14201